Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Candel Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 06/29/2023 |
4
| Gaeta Renee (Director) has filed a Form 4 on Candel Therapeutics, Inc.|
Txns:
| Granted 14,240 options to buy
@ $1.22, valued at
$17.4k
|
|
| 06/29/2023 |
4
| Nguyen Diem (Director) has filed a Form 4 on Candel Therapeutics, Inc.|
Txns:
| Granted 14,240 options to buy
@ $1.22, valued at
$17.4k
|
|
| 06/29/2023 |
4
| Manning Paul B (Director) has filed a Form 4 on Candel Therapeutics, Inc.|
Txns:
| Granted 14,240 options to buy
@ $1.22, valued at
$17.4k
|
|
| 06/29/2023 |
4
| Martell Christopher (Director) has filed a Form 4 on Candel Therapeutics, Inc.|
Txns:
| Granted 14,240 options to buy
@ $1.22, valued at
$17.4k
|
|
| 06/29/2023 |
4
| Benz Edward J. JR (Director) has filed a Form 4 on Candel Therapeutics, Inc.|
Txns:
| Granted 14,240 options to buy
@ $1.22, valued at
$17.4k
|
|
| 06/29/2023 |
4
| PAPA JOSEPH C (Director) has filed a Form 4 on Candel Therapeutics, Inc.|
Txns:
| Granted 14,240 options to buy
@ $1.22, valued at
$17.4k
|
|
| 06/29/2023 |
4
| Aguilar-Cordova Estuardo (Director) has filed a Form 4 on Candel Therapeutics, Inc.|
Txns:
| Granted 14,240 options to buy
@ $1.22, valued at
$17.4k
|
|
| 06/29/2023 |
4
| Nabel Gary J. (Director) has filed a Form 4 on Candel Therapeutics, Inc.|
Txns:
| Granted 14,240 options to buy
@ $1.22, valued at
$17.4k
|
|
| 06/29/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 06/13/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 06/09/2023 |
4
| Loggia Nicoletta (Director) has filed a Form 4 on Candel Therapeutics, Inc.|
Txns:
| Granted 28,480 options to buy
@ $1.51, valued at
$43k
|
|
| 06/09/2023 |
3
| Loggia Nicoletta (Director) has filed a Form 3 on Candel Therapeutics, Inc. |
| 06/08/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/23/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/23/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/19/2023 |
8-K
| Investor presentation |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/09/2023 |
8-K
| Shareholder Nominations Pursuant to Exchange Act Rule 14a-11, Financial Statements and Exhibits Interactive ... |
| 05/02/2023 |
4
| Tak Paul Peter (CEO) has filed a Form 4 on Candel Therapeutics, Inc.|
Txns:
| Granted 180,000 options to buy
@ $1.29, valued at
$232.2k
|
|
| 05/02/2023 |
4
| Tyagarajan Seshu (Chief Technology Officer) has filed a Form 4 on Candel Therapeutics, Inc.|
Txns:
| Granted 90,000 options to buy
@ $1.29, valued at
$116.1k
|
|
| 05/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/02/2023 |
4
| Amello Jason (CFO) has filed a Form 4 on Candel Therapeutics, Inc.|
Txns:
| Granted 90,000 options to buy
@ $1.29, valued at
$116.1k
|
|
| 05/01/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 04/17/2023 |
8-K
| Quarterly results |
| 03/30/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/30/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/30/2023 |
8-K
| Quarterly results |
| 02/22/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/09/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 12/12/2022 |
4
| Barone Francesca (Chief Scientific Officer) has filed a Form 4 on Candel Therapeutics, Inc.|
Txns:
| Bought 1,238 shares
@ $1.61, valued at
$2k
|
|
|
|
|